Holen Sie sich die Stockscreener-App
27.11
0.23%
0.11
Handel nachbörslich:
27.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
U.S. Opioid Withdrawal Treatment Market Emerging Trends - openPR.com
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
First Week of June 20th Options Trading For Alkermes (ALKS) - Nasdaq
Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors - simplywall.st
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
Alkermes price target raised to $35 from $34 at BofA - MSN
Alkermes to Report First Quarter Financial Results on May 1, 2025 - GuruFocus
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Alkermes' CFO Iain Brown passes away - MSN
Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus
Alkermes' CFO Iain Brown passes away (ALKS:NASDAQ) - Seeking Alpha
Alkermes CFO Iain M. Brown passes away By Investing.com - Investing.com India
AlkermesCFO Iain M. Brown Passes AwaySEC Filing - marketscreener.com
Alkermes CFO Iain M. Brown passes away - Investing.com
Alkermes (ALKS) announces passing of Chief Financial Officer - StreetInsider
Alkermes plc Announces Demise of Iain M. Brown, Chief Financial Officer - marketscreener.com
Massachusetts biotech company cuts 90% of its workforce - NBC Boston
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io
Alkermes to Participate in Two Upcoming Investor Conferences - Seeking Alpha
Alkermes To Present At Needham Virtual Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Opioid Use Disorder Market Generated Opportunities, Future - openPR.com
Alcohol Addiction Treatments Market Detailed in New Research - openPR.com
Opioid Withdrawal Treatment Market Emerging Trends and Growth - openPR.com
Relative Strength Alert For Alkermes - Nasdaq
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 - MSN
RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
Alkermes Begins Idiopathic Hypersomnia Study On ALKS 2680 - Barchart.com
Nanotechnology Drug Delivery Market Exclusive Trends Analysis - openPR.com
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - Sharecast News
Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia - MarketScreener
(ALKS) Trading Report - news.stocktradersdaily.com
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - MarketScreener
What 5 Analyst Ratings Have To Say About Alkermes - Benzinga
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Liposomal Drug Delivery Market Detailed In New Research Report - openPR.com
First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq
Controlled Release Drug Delivery Market to Witness Massive - openPR.com
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
4.89%
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):